The occurrence of cancer during childhood represents one of the leading causes of death within the pediatric and adolescent age group. It is estimated that approximately 8000 children will be diagnosed annually with cancer in the United States. Epidemiologic research addressing the etiology of childhood cancer has been limited because of the difficulties in identifying a sufficiently large study population. Moreover, the use of retrospectively ascertained childhood cancer cases in epidemiologic investigations has restricted the incorporation of biological and clinical parameters. The Childrens Cancer Group has developed an active program in epidemiologic research, with over a decade of experience demonstrating the feasibility and strengths of conducting analytic epidemiologic studies within a cooperative clinical trials network. The availability of detailed clinical and biologic data on cases diagnosed within the cooperative group facilitates the transfer of state-of-the-art technology to epidemiologic research. -Environ Health Perspect 103(Suppl 6): 111-116 (1995) 
Introduction
Approximately 8000 children in the United States are diagnosed annually with cancer (1) . The incidence of cancer in children less than 15 years of age is approximately 13 per 100,000 for whites and 11 per 100,000 for blacks. While the absolute number of childhood cancer cases is low, when compared to the number of adult cancers, U.S. mortality data demonstrate that cancer is the second leading cause of death in children, second only to accidents (2) . It can be estimated that approximately one in every 400 individuals living in the United States will develop cancer before age 15 .
Data from the Surveillance Epidemiology and End Results Program indicate a gradual but continuous increase in the incidence rates of childhood cancers (3, 4) . These increases are most apparent for leukemia and brain tumors, the two diagnoses that comprise approximately 50% of cases in the 0 to 14 age group. There has been considerable speculation on (5) .
The types and distributions of the malignancies seen in the pediatric and adolescent age groups differ substantially from those seen in adults. Although childhood cancers represent less than 2% of all cancers that occur in the United States, the unique clinical and biologic features of pediatric malignancies have contributed substantially to our understanding of cancer. Most of the contribution of pediatric cancers has been in providing insights into the genetic events associated with malignant transformation. Tumor suppressor genes, first identified in retinoblastoma (a tumor with an annual incidence of less than 5 per million), have now been described in Wilms' tumor, rhabdomyosarcoma, and some adult malignancies (6) (7) (8) . Childhood cancers have also provided important information on familial cancer associations and syndromes (9) (10) . In contrast to these genetic and familial findings, childhood cancers have contributed much less to the understanding of the environmental aspects of cancer.
Recognizing the difficulties of conducting epidemiologic studies Experience in CCG has shown that using the methodologic approach adopted, case-control studies designed to test specific hypotheses and/or generate hypotheses within selected childhood cancers can be successfully conducted. Impressively high rates of participation (both physician and parent) have been achieved. For example, in the current case-control study of childhood ALL (E-15), where over 2300 cases have been identified, permission to contact parents was received from physicians of 98.4% of eligible cases. Physician refusal occurred in only 1.1% and parent refusal, via the physician, in 0.5%. Of the parents contacted, 97.5% participated in the study. Using the method of random digit dialing for control selection, the participation rate in CCG studies has averaged approximately 80%.
In addition to the availability of the large numbers of cases, one of the major advantages of conducting epidemiologic studies in CCG is the clinical and biological data that can be incorporated into the design of the epidemiologic investigation. Parental Occupation and Childhood Cancer (CCG-E16). This study uses the unique data source that contains information from a self-administered questionnaire on 3549 children with cancer and 839 healthy children (E04). The cancers we will study are acute lymphoblastic leukemia, neuroblastoma, acute myeloid leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, Wilms' tumor, osteosarcoma, astrocytoma, primitive neuroectodermal tumor (PNET)/medulloblastoma, rhabdomyosarcoma, germ cell and gonadal tumor, hepatoblastoma, Ewing's sarcoma, and histiocytosis X. The following specific hypotheses will be tested: a) children with Wilms' tumor, brain tumor, and other cancers are more likely than controls to have parents who worked in metal-related occupations or industries; b) children with neuroblastoma, brain tumor, and other cancers are more likely than controls to have parents employed in the electric and electronic industry; c) children with brain tumor, acute myeloid leukemia, and other cancers are more likely than controls to have parents employed in agriculture or occupations with exposure to pesticides.
Epidemiology of Neuroblastoma (CCG-E18). The major purpose of the CCG-E18 study is to examine the relationships between specific environmental exposures and the occurrence of neuroblastoma. The specific aim of the study is to evaluate hypothesized risk factors, including maternal use of drugs, sex hormones, alcohol, and diuretics during pregnancy. The analysis of maternal drug use during pregnancy will include a special evaluation of the potential for these drugs to result in transplacental N-nitroso compound exposure. In addition, paternal employment in the electronics industry and occupational exposure to electromagnetic fields will be examined. Other risk factors previously found to be associated with neuroblastoma such as maternal age, length of gestation, birth weight, and family socioeconomic status will be evaluated. In addition, this study will collect information on additional potential risk factors that may be used to develop new etiologic hypotheses (such as family medical history, neonatal, gestational, and delivery history, and household environmental exposures); and evaluate the above potential risk factors separately for subgroups of patients defined by clinical, biologic, and genetic markers such as cytogenetic abnormality and n-myc oncogene amplification.
Current and Future Research Objectives
Through continued reliance on externallyfunded investigations (primarily RO 
